Related Experiment Videos
[Diphenylhydantoin stimulation test in Wilson's disease]
Psychiatrie, Neurologie, Und Medizinische Psychologie
|September 1, 1979
Summary
Diphenylhydantoin (DPH) does not significantly affect serum ceruloplasmin levels. Therefore, DPH is not suitable for diagnosing Wilson's disease, especially in early stages, as healthy individuals also show no ceruloplasmin increase.
Area of Science:
- Biochemistry
- Clinical Chemistry
- Pharmacology
Context:
- Investigating the relationship between diphenylhydantoin (DPH) and ceruloplasmin levels.
- Assessing DPH's potential as a diagnostic tool for Wilson's disease.
- Evaluating ceruloplasmin serum concentrations in patients undergoing DPH therapy.
Purpose:
- To determine if diphenylhydantoin (DPH) influences serum ceruloplasmin levels.
- To evaluate the utility of DPH in stimulating ceruloplasmin for Wilson's disease diagnosis.
- To compare ceruloplasmin levels in patients newly stabilized on DPH versus those at steady-state.
Summary:
- Serum ceruloplasmin and diphenylhydantoin (DPH) levels were analyzed in patients newly stabilized on DPH (N=6) and at steady-state (N=25).
- No significant DPH-dependent alteration in serum ceruloplasmin was observed across patient groups.
- The study concludes DPH is unsuitable for stimulating ceruloplasmin or diagnosing Wilson's disease, as healthy individuals also exhibit no ceruloplasmin increase.
Impact:
- Challenges the use of DPH as a diagnostic agent for Wilson's disease.
- Highlights the need for alternative diagnostic markers for preclinical Wilson's disease.
- Provides evidence against DPH-induced ceruloplasmin stimulation as a reliable diagnostic method.